An observational study in Otitis Media Chronic and Cholesteatoma, sponsored by Abant Izzet Baysal University. Status unknown at 1 site in Turkey. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2019-05-21.
Sponsored by Abant Izzet Baysal University · Observational
The aim of this study is to investigate the levels of sclerostin in patients with cholesteatoma. So far, there is no study showing the levels of sclerostin in cholesteatoma. The investigators hope that the results of our study will start new processes that can be used in the clinic.
Chronic otitis media (COM) is the perforation of the eardrum and mucosal inflammation of the space in the middle ear and the air cavities of the temporal bone over a period of three months. Although COM is defined as a multifactorial disease, its etiopathogenesis has not been fully elucidated. Cholesteatoma is a condition that disrupts the balance between bone formation and resorption in COM. The cholesteatoma is a destructive squamous epithelial lesion of temporal bone, it gradually expands and leads to serious complications by the destruction of near bone structures, ossicular chain and otic capsule. A growing debate examines the role of bone formation and destruction with osteoblasts, osteocytes and osteoclast cells in cholesteatoma formation. Sclerostin is a glycoprotein that plays a role in the regulation of bone metabolism secreted by osteocytes. Antibodies directed against sclerostin stimulate bone formation and represent a new therapeutic option for the treatment of increased bone resorption diseases, such as osteoporosis and generalized bone loss, inflammatory diseases with cartilage damage. The aim of this study is to investigate the levels of sclerostin in patients with cholesteatoma. So far, there is no study showing the levels of sclerostin in cholesteatoma. The investigators hope that the results of our study will start new processes that can be used in the clinic.
246 studies on the registry are indexed under Otitis; 21 are open to participants now.
This study's planned enrollment of 75 is below the median of 165 across 63 observational studies indexed under Otitis.
Browse Otitis studies →Abant Izzet Baysal University is the lead sponsor of 242 studies on the registry; 64 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The experimental group of this study consisted of 75 patients who applied to AIBU Bolu Izzet Baysal Training and Research Hospital Ear Nose Throat Clinic and regularly followed up. A control group of approximately 50 people, which is demographically similar, and patients whose scheduled for operation with other causes.
cholesteatoma chronic otitis media
Exclusion Criteria:
Acute infection Malignancy
patients with chronic otitis media without cholesteatoma
Diagnostic Test: serum for sclerostin ELISA test
patients with chronic otitis media whose cholesteatoma
Diagnostic Test: serum for sclerostin ELISA test
patients scheduled to operation with diagnosis of other causes
Diagnostic Test: serum for sclerostin ELISA test
Blood sample to measure serum sclerostin level
change of the levels of sclerostin in cholesteatoma at 1 month
So far, there is no study showing the levels of sclerostin in cholesteatoma. The investigators hope that the results of our study will initiate new processes that can be used in clinical applications.
Time frame: 1 month
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abant Izzet Baysal University